Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy

Diabetes

Volumn 55, Issue 1, 2006, Pages 225-233

  Susztak, Katalin ^a   Raff, Amanda C ^a   Schiffer, Mario ^a   Böttinger, Erwin P ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CASPASE 3; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR SPACE; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SPACE; MALE; MESANGIUM; MITOCHONDRION; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 33644783770     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.01.06.db05-0894     Document Type: Article

References (50)

1. USRDS: the United States Renal Data System. Am J Kidney Dis 42:1-230, 2003
2. Drummond K, Mauer M: The early natural history of nephropathy in type 1 diabetes. II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580-1587, 2002
3. Mauer M, Drummond K: The early natural history of nephropathy in type 1 diabetes. I. Study design and baseline characteristics of the study participants. Diabetes 51:1572-1579, 2002
4. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M: The early natural history of nephropathy in type 1 diabetes. III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54:2164-2171, 2005
5. Fioretto P, Steffes MW, Brown DM, Mauer SM: An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 20:549-558, 1992
6. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99:8301-8305, 2002
7. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762-1764, 2003
8. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM: Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14:1383-1395, 2003
9. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
10. Colwell JA: Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes 45 (Suppl. 3):S87-S90, 1996
11. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54:1626-1634, 2005
12. Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 15 (Suppl. 1):S55-S57, 2004
13. Ziyadeh FN, Sharma K: Overview: combating diabetic nephropathy. J Am Soc Nephrol 14:1355-1357, 2003
14. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342-348, 1997
15. Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 42:1341-1344, 1999
16. Petermann AT, Krofft R, Blonski M, Hiromura K, Vaughn M, Pichler R, Griffin S, Wada T, Pippin J, Durvasula R, Shankland SJ: Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 64:1222-1231, 2003
17. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65:30-39, 2004
18. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285:F40-F48, 2003
19. Bottinger EP, Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol 13:2600-2610, 2002
20. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108:807-816, 2001
21. Schiffer M, Mundel P, Shaw AS, Bottinger EP: A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-betainduced apoptosis. J Biol Chem 279:37004-37012, 2004
22. Cotter MA, Cameron NE: Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 73:1813-1824, 2003
23. Beswick RA, Dorrance AM, Leite R, Webb RC: NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38:1107-1111, 2001
24. Park YM, Park MY, Suh YL, Park JB: NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosteroneinfused rats. Biochem Biophys Res Commun 313:812-817, 2004
25. Mundel P, Heid HW, Mundel TM, Kruger M, Reiser J, Kriz W: Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol 139:193-204, 1997
26. Breyer MD, Bottinger E, Brosius FC III, Coffman TM, Harris RC, Heilig CW, Sharma K: Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27-45, 2005
27. Susztak K, Sharma K, Schiffer M, McCue P, Ciccone E, Bottinger EP: Genomic strategies for diabetic nephropathy. J Am Soc Nephrol 14:S271-S278, 2003
28. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284:F1138-F1144, 2003
29. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP: Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2:e45, 2005
30. Kang BP, Frencher S, Reddy V, Kessler A, Malhotra A, Meggs LG: High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. Am J Physiol Renal Physiol 284:F455-F466, 2003
31. Vincent AM, McLean LL, Backus C, Feldman EL: Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 19:638-640, 2005
32. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kajstura J: Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50:2363-2375, 2001
33. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS: Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67:1890-1898, 2005
34. Greiber S, Munzel T, Kastner S, Muller B, Schollmeyer P, Pavenstadt H: NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 53:654-663, 1998
35. Susztak K, Bottinger E, Novetsky A, Liang D, Zhu Y, Ciccone E, Wu D, Dunn S, McCue P, Sharma K: Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53:784-794, 2004
36. Steffes MW, Schmidt D, McCrery R, Basgen JM: Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 59:2104-2113, 2001
37. Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 111:877-885, 2003
38. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R: Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60:957-968, 2001
39. Rennke HG: How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int Suppl 45:S58-S63, 1994
40. Kriz W: Progression of chronic renal failure in focal segmental glomerulosclerosis: consequence of podocyte damage or of tubulointerstitial fibrosis? Pediatr Nephrol 18:617-622, 2003
41. Kriz W: Evolving role of the podocyte in chronic renal failure. Kidney Blood Press Res 20:180-183, 1997
42. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54:687-697, 1998
43. Kriz W, Lemley KV: The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8:489-497, 1999
44. Pavenstadt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 83:253-307, 2003
45. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
46. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
47. Goldman EH, Chen L, Fu H: Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation. J Biol Chem 279:10442-10449, 2004
48. Koshikawa M, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshioka T, Nagae T, Yokoi H, Kawachi H, Shimizu F, Sugawara A, Nakao K: Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16:2690-2701, 2005
49. Hayashi T, Juliet PA, Kano-Hayashi H, Tsunekawa T, Dingqunfang D, Sumi D, Matsui-Hirai H, Fukatsu A, Iguchi A: NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diabetes Obes Metab 7:334-343, 2005
50. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97:8015-8020, 2000